SCHEMBL2551479

SCHEMBL2551479

CNC(=O)Nc1cc(Oc2ccc([N+](=O)[O-])c(C)c2C)ccn1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCK P35557 5/20 0.56
POLB P06746 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 1/20 0.42
MAPT P10636 1/20 0.41
LMNA P02545 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDR P35968 6/20 0.39
BRAF P15056 5/20 0.39
MEN1 O00255 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
KMT2A Q03164 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29788823 1.00 GCK (0.56) GCKPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL29083255 0.89 MEN1 (0.45) GCKPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL29083258 0.87 KMT2A (0.44) GCKLMNAKDRBRAFKMT2A
SCHEMBL29083248 0.86 POLB (0.42) GCKPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL2548106 0.86 GCK (0.57) GCKPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL29083232 0.86 ALDH1A1 (0.42) GCKPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL2555515 0.85 GCK (0.60) GCKPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL29083242 0.85 KDR (0.52) KDRBRAF
SCHEMBL13504178 0.84 RAB9A (0.53) POLBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL2554844 0.83 LMNA (0.45) GCKPOLBNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114907339-B 4- (4-aminophenoxy) pyridin-2-amine derivatives and use thereof 成都奥睿药业有限公司 2023-07-14 CN disclosed
CN-114907339-A 4- (4-aminophenoxy) pyridin-2-amine derivatives and uses thereof 成都奥睿药业有限公司 2022-08-16 CN disclosed
EP-2556068-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2019-01-23 EP disclosed
US-9024041-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-05-05 US disclosed
US-20130040962-A1 P38 MAP Kinase Inhibitors RESPIVERT LTD (GB) 2013-02-14 US disclosed
EP-2556068-A1 P38 MAP KINASE INHIBITORS Respivert Limited (GB) 2013-02-13 EP disclosed
WO-2011124930-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040962-A1 P38 MAP Kinase Inhibitors MAPK15, MAPK1, MAP3K15 GCK 1335/4885POLB 1398/4885NPC1 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.